Equity L/S Analyst | Forensic Accounting | India, Yellowstone Equity

Ankit Agrawal, CFA

Equity L/S Analyst | Forensic Accounting | India

Creating Wealth through Alpha and Compounding

Yellowstone Equity

Providing unbiased and independent research on Indian equities to global institutions and individual investors


-------------
Regulatory Disclosure: 
Note that Ankit Agrawal (Proprietor of Yellowstone Equity) is a SEBI registered Research Analyst (Registration No.: INH000007216). Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Research Analyst Contact Details:
Address: A-412, Shilp Aaron, Sindhu Bhavan Road, Ahmedabad, Gujarat - 380059
Email: services@yellowstoneequity.com
Mobile: +91-7575817289

Compliance/Grievance Officer:
Name: Ankit Agrawal
Email: services@yellowstoneequity.com
Mobile: +91-7575817289
-------------

Equity Bottom-Up

HealthCare Global Enterprises / Equity Bottom-Up

<ul>
<li>With new centers scaling up, HCG reported industry leading revenue growth (10% QoQ). With capex cycle behind us, HCG is poised to post strong profitability, cash flow and growth.</li>
<li>Over the past 3 quarters, HCG has been consistently reporting highest-ever revenue. Its Q2FY22 revenue is highest ever in its history, even with exclusion of COVID and vaccination revenues. </li>
<li>HCG also reported its highest ever EBITDA of INR 65cr, leading to positive PAT (excluding non-recurring gains) after a long hiatus of 13 quarters.</li>
</ul>


With new centers scaling up, HCG reported industry leading revenue growth (10% QoQ). With capex cycle behind us, HCG is poised to post strong profitability, cash flow and growth.
Over the past 3 quarters, HCG has been consistently reporting highest-ever revenue. Its Q2FY22 revenue is highest ever in its history, even with exclusion of COVID and vaccination revenues. 
HCG also reported its highest ever EBITDA of INR 65cr, leading to positive PAT (excluding non-recurring gains) after a long hiatus of 13 quarters.


HCG: On Track For Sustainable Growth and Profitability

<p><a href="https://www.smartkarma.com/entities/healthcare-global-enterprises-limited" target="_blank" data-smartkarma-citation="entities:23983:1" rel="noopener">HealthCare Global Enterprises (HCG IN)</a> announced yesterday night that it has sold off its 38.5% (34.5% on a fully diluted basis) stake in Strand Life Sciences ("Strand") to Reliance Strategic Business Ventures, a 100% subsidiary of <a href="https://www.smartkarma.com/entities/reliance-industries-ltd" target="_blank" data-smartkarma-citation="entities:198:1" rel="noopener">Reliance Industries (RIL IN)</a>. Strand is a genomics based research and diagnostics company.</p>

HealthCare Global Enterprises (HCG IN) announced yesterday night that it has sold off its 38.5% (34.5% on a fully diluted basis) stake in Strand Life Sciences ("Strand") to Reliance Strategic Business Ventures, a 100% subsidiary of Reliance Industries (RIL IN). Strand is a genomics based research and diagnostics company.

<p>Post equity infusion last year from CVC, a private equity player, HCG has been getting more and more disciplined in its capital allocation. In Q4FY21, it wrote-off investments related to most of its medium-term expansion plans and is now focusing solely on consolidating its existing operations, which in itself provides strong growth potential at high incremental ROC given that most of the capex is now behind us. Operational leverage from increased utilization of new centers should help boost margins.</p>

Post equity infusion last year from CVC, a private equity player, HCG has been getting more and more disciplined in its capital allocation. In Q4FY21, it wrote-off investments related to most of its medium-term expansion plans and is now focusing solely on consolidating its existing operations, which in itself provides strong growth potential at high incremental ROC given that most of the capex is now behind us. Operational leverage from increased utilization of new centers should help boost margins.

External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

External broker reports(aggregated public sources)

<p>About the stock: HCG operates one of the largest private cancer care networks in India with end-to-end solutions available under a single corporate entity. This consists of 22 comprehensive cancer centres that provide a single point destination for complete cancer care.</p>
<ul>
<li>Most centres are on a lease or rental basis with some in partnership with local doctors or hospitals</li>
<li>Owing to exclusive agreement with vendors, HCG procures equipment on a deferred payment basis</li>
</ul>
<div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

About the stock: HCG operates one of the largest private cancer care networks in India with end-to-end solutions available under a single corporate entity. This consists of 22 comprehensive cancer centres that provide a single point destination for complete cancer care.

Most centres are on a lease or rental basis with some in partnership with local doctors or hospitals
Owing to exclusive agreement with vendors, HCG procures equipment on a deferred payment basis

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Healthcare Global Enterprises: Recovery in Q1 with Better Margins

Smartkarma Research Team, Smartkarma

Smartkarma Research

Smartkarma Research Team

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<p>In our next Smartkarma Corporate Webinar, we are glad to welcome Niraj Didwania, Head of Corporate Development and Investor Relations at <a href="https://www.smartkarma.com/entities/healthcare-global-enterprises-limited/overview" target="_blank" rel="noopener">HealthCare Global Enterprises Limited (HCG IN)</a>. Niraj will share a short presentation about the company and have a fireside chat with Smartkarma Insight Provider <a href="https://www.smartkarma.com/profiles/ankit-agrawal-cfa" target="_blank" rel="noopener">Ankit Agrawal, CFA</a>, followed by a live Q&amp;A session.</p><h3>The Corporate Webinar will be hosted live on Tuesday, 13 April 2021, 14:30 IST / 17:00 SGT.</h3><p>It will also be recorded for future reference by Smartkarma and HCG.</p><div class="content-highlight"><h2><a href="https://share.hsforms.com/1H9pFZOB-RF2J00kbvMmxcw2c5gj?zoom_webinar_id=88465179775" target="_blank" rel="noopener">Register for the Webinar here</a></h2></div><p>Corporate Webinars by <a href="https://www.smartkarma.com/home/corporate-solutions/" target="_blank" rel="noopener">Smartkarma Corporate Solutions</a> feature discussions with IROs and Executives, discussing their companies, the challenges they face, and the opportunities in their sectors and markets.</p>

In our next Smartkarma Corporate Webinar, we are glad to welcome Niraj Didwania, Head of Corporate Development and Investor Relations at HealthCare Global Enterprises Limited (HCG IN). Niraj will share a short presentation about the company and have a fireside chat with Smartkarma Insight Provider Ankit Agrawal, CFA, followed by a live Q&amp;A session.The Corporate Webinar will be hosted live on Tuesday, 13 April 2021, 14:30 IST / 17:00 SGT.It will also be recorded for future reference by Smartkarma and HCG.Register for the Webinar hereCorporate Webinars by Smartkarma Corporate Solutions feature discussions with IROs and Executives, discussing their companies, the challenges they face, and the opportunities in their sectors and markets.

Smartkarma Corporate Webinar | HealthCare Global: New Opportunities in Cancer Care in India

India

HealthCare Global Enterprises Limited provides medical and surgical hospital services. The Hospital offers cancer care, chemotherapy, cyberknife surgery, surgical, radiation, and medical oncology services. HealthCare Global Enterprises operates worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

HealthCare Global Enterprises (HCG IN)

HCG: On Track For Sustainable Growth and Profitability

In line with our thesis, HCG is poised to post strong growth, profitability and cash flows as its new centers scale up. With capex cycle behind us...

Ankit Agrawal, CFA

HCG: Sale of Strand Business

HCG announced sale of its stake in Strand. At the same time, it also acquired Strand's specialty oncology diagnostics segment to continue its...

Ankit Agrawal, CFA

HCG: Getting Disciplined

Over last 1Y, HCG has restructured itself significantly to streamline its capital allocation and consolidate its existing operations. With capex...

Ankit Agrawal, CFA

Healthcare Global Enterprises: Recovery in Q1 with Better Margins

HCG operates one of the largest private cancer care networks in India with end-to-end solutions available under a single corporate entity. This...

ICICI Securities Limited

Smartkarma Corporate Webinar | HealthCare Global: New Opportunities in Cancer Care in India

On 13 April, 5pm SGT, join us in welcoming Niraj Didwania, Head of Corporate Development and Investor Relations at HealthCare Global Enterprises,...

Smartkarma Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)